ClinicalTrials.gg
CompletedNCT02242955DIAMAUpdated Apr 22, 2026

Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse

An interventional study of Diazepam in Alcoholism, sponsored by University Hospital, Lille. Completed at 2 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Alcoholism with a site in France — 24 open to participants now, 25 under way, 1 of them phase 3. Alcoholism · France.

Enrollment
54th of 58
26 · median 153
Started
2014
with 5 others
No phase
42 of 94
15 open now
Registered
19th of 94
by date
Lead sponsor
7 of 94
University Hospital, Lille

Among the 94 studies in Alcoholism with a site in France, this one is the 54th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2014, is one of 42 with no phase, and was the 19th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

24 of the 94 studies in Alcoholism with a site in France are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Alcoholism with a site in France, or all of them as a file.
02

Study summary

Alcohol-dependence is a medical condition that can lead to the occurrence of an alcohol withdrawal syndrome (AWS) in case of alcohol drinking cessation. Diazepam is the reference medication for preventing or treating AWS. The recommended average diazepam treatment duration is usually around one week, and this duration is generally not considered to impact the subsequent relapse rate in alcohol drinking.

However, several previous studies have found that patients experienced frequent anxious symptoms during the weeks following detoxification. Such symptoms may foster early relapse in alcohol drinking. Furthermore, it has been suggested that this anxiety could pertain to late withdrawal symptoms.

The DIAMA study hypothesizes that extending the diazepam detoxification treatment to one month can significantly reduce the cumulated relapse rate in alcohol drinking over the three following months.

Read the detailed description
  • inclusion at Day 5 of the outpatient alcohol detoxification procedure
  • randomization in two arms: 1) "10 day - diazepam"; and 2) "30 day - diazepam"
  • tapering of diazepam over the 10 days following the beginning of the detoxification procedure in the first arm; tapering of diazepam over the 30 days following the beginning of the detoxification procedure in the second arm.
  • 3-month-long follow-up after detoxification. Objective of maintaining abstinence from alcohol. No use of additional anticraving drug. Standardised psychotherapeutic support based on the BRENDA model.
  • Longitudinal recording of alcohol consumption using the Alcohol Timeline Follow-Back method.
  • Assessment of craving (Obsessive-Compulsive Drinking Scale) and anxiety (State-Trait Anxiety Inventory; Hamilton Anxiety Rating Scale) at Days 5 (baseline), 15, 30, 60 and 90 (final assessment).
03

Conditions studied

  • Alcoholism

Keywords

  • Alcohol-dependence
  • Relapse
  • Detoxification
  • Diazepam
  • Benzodiazepines
  • Anxiety
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -Tr criteria for alcohol dependence
  • Diazepam-based outpatient detoxification procedure started 5 days prior to inclusion

Exclusion criteria

Exclusion Criteria:

  • for outpatient detoxification
  • occurrence of delirium tremens or seizures during the pre-inclusion period
  • contraindication for using diazepam
  • any other criteria for substance abuse or dependence in the preceding year (except from tobacco)
  • concurrent axis-I psychiatric disorder
  • concurrent neurological pathology or cognitive impairment
  • concurrent social risk, i.e., homelessness or social isolation
  • liver failure, cancer, or significant breathing disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    AD = "as-usual diazepam"

    Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).

    Drug: Diazepam

  • Experimental
    PD = "prolonged diazepam"

    Diazepam will be slowly tapered to be stopped at day 30

    Drug: Diazepam

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of relapse in alcohol drinking

    Proportion of patients who will have reported any alcohol drinking over the three months following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).

    Time frame: at 3 months

Secondary outcomes

  1. Occurrence of adverse events

    Time frame: Over the first month, at 3 months

  2. Rate of relapse in heavy drinking

    Proportion of patients who will have reported at least one heavy drinking day, i.e., ≥ 50 g of alcohol in a day, over the first month and the three month following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).

    Time frame: at 1 month; at 3 months

  3. Ratio of drinking days/heavy drinking days

    Time frame: over the first month, at 3 months

  4. Level of self-reported anxiety

    Score of self-reported anxiety using the State-Trait Anxiety Inventory

    Time frame: at 1 month; at 3 months

  5. Level of clinician-assessed anxiety

    Score of anxiety using the Hamilton Anxiety Rating Scale

    Time frame: at 1 month; at 3 months

  6. Level of alcohol craving

    Level of alcohol craving using the Obsessive-Compulsive Drinking Scale

    Time frame: at 1 month; at 3 months

  7. Average weekly alcohol consumption

    Time frame: at 1 month; at 3 months

07

Study locations

2 sites
  • Department of Addiction Medicine
    Lille, 59037, France
  • Outpatient Addiction Center "CSAPA - Le Pari"
    Lille, 59037, France
08

References and documents

Publications

  • Simioni N, Labreuche J, Behal H, Cottencin O, Rolland B. Thirty- Versus Ten-Day Diazepam Treatment for Alcohol Detoxification and a Comparison of Drinking Patterns, Craving, and Anxiety for up to 12 Weeks: A "Proof-of-Concept" Open-Label Randomized Controlled Trial. J Clin Psychopharmacol. 2017 Dec;37(6):722-728. doi: 10.1097/JCP.0000000000000786. PubMed 28984747 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2014
First posted
Sep 17, 2014
Start
Jul 2014
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02242955
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Jul 2014
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Apr 22, 2026

Study contacts

Benjamin ROLLAND, MD, PhD
principal investigator · University Hospital of Lille (CHU Lille), France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion